甲胎蛋白及其异质体、磷脂酰肌醇蛋白聚糖3和基质金属蛋白酶2联合检测在肝细胞癌中的诊断价值

doi:10.19871/j.cnki.xfcrbzz.2022.04.008

新发传染病电子杂志 ›› 2022, Vol. 7 ›› Issue (4): 33-36.doi: 10.19871/j.cnki.xfcrbzz.2022.04.008

甲胎蛋白及其异质体、磷脂酰肌醇蛋白聚糖3和基质金属蛋白酶2联合检测在肝细胞癌中的诊断价值

庞文箫¹, 李继科¹, 陈廷玉², 赵勇², 魏国²

1.成都市公共卫生临床医疗中心传染病研究室,成都 610066;
2.成都市公共卫生临床医疗中心普外科,成都 610066

收稿日期:2022-05-25 发布日期:2023-02-20
通讯作者: 魏国,Email：plantonic@163.com
基金资助:
1.四川省科技厅科技项目(2018SZ0086); 2.成都市科技局项目(2015-HM01-00510-SF); 3.四川省医学会项目(Q15077、017SZJA04)

The value of AFP combined with AFP-L3, GPC3 and MMP2 detection in the diagnosis of hepatocellular carcinoma

Pang Wenxiao¹, Li Jike¹, Chen Tingyu², Zhao Yong², Wei Guo²

1. Laboratory of Infectious Diseases, Public Health Clinical Center of Chengdu, Chengdu 610066, China;
2. The Department of General Surgery, Public Health Clinical Center of Chengdu, Chengdu 610066, China

Received:2022-05-25 Published:2023-02-20

摘要/Abstract

摘要： 目的检测血清中甲胎蛋白（AFP）及其异质体（AFP-L3）、磷脂酰肌醇蛋白聚糖3（GPC3）和基质金属蛋白酶2（MMP2）的表达水平,探讨四项指标的联合检测对HCC的诊断价值。方法选取2019年12月至2020年12月于成都市公共卫生临床医疗中心住院的60例肝细胞癌患者为肝癌组,均经肝组织学检查确诊。60例肝硬化患者为肝硬化组,60例慢性乙型肝炎患者为慢性乙肝组,诊断符合防治指南。选择同期体检的60例健康者作为对照组。使用化学发光法及酶联免疫双抗体夹心法分别检测外周血清AFP及AFP-L3、GPC3、MMP2的水平。统计分析各组研究对象血清标志物的差异,计算联合检测的诊断效率。结果肝癌组的血清AFP、AFP-L3和GPC3、MMP2水平均明显高于慢性乙肝组、肝硬化组及对照组（M=122.3μg/L、88.33μg/L、53.45pg/ml、701.3μg/L;H=125.8、167.5、209.4、210.4;均P<0.05）。4项指标联合检测的诊断准确率为89.3%,灵敏度与特异度分别为84.87%与84.59%,其曲线下面积（AUC）为0.905,均高于单项检测,差异有统计学意义（均P<0.05）。结论 AFP及AFP-L3、GPC3和MMP2均为HCC的危险因素,其联合检测可以提高HCC的阳性检出率,有助于其高危患者肿瘤的早期诊断、治疗,延长患者生存时间,提高生存率。

关键词: 甲胎蛋白, 甲胎蛋白异质体, 磷脂酰肌醇蛋白聚糖3, 基质金属蛋白酶2, 肝细胞癌

Abstract: Objective The purpose of detecting the expression of serum AFP,AFP-L3, GPC3 and MMP2 was to study the diagnostic value of the combined detection of four indicators in HCC．Method 60 HCC patients,60 case of liver cirrhosis patients,60 cases of chronic viral hepatitis B ( HBV) patients and 60 healthy controls were selected from Outpatients in Public Health Clinical Center of Chengdu from December 2019 to December 2020.The serum AFP,AFP-L3 and GPC3,MMP2 detected with chemiluminescence and enzyme-linked immunosorbent double antibody sandwich method, respectively. Analyzed the differences of serum marker in each group, and the diagnostic efficiency of combined detection was calculated. Result The levels of serum AFP,AFP-L3,GPC3,and MMP2 in HCC patients were significantly higher than those of other non-HCC groups,and the differences were statistical significance(M =122.3 μg/L, 88.33 μg/L, 53.45 pg/ml, 701.3 μg/L;H =125.8, 167.5, 209.4, 210.4; P< 0.05). The diagnostic accuracy of the combined detection of four indicators was 89.3%, the sensitivity and specificity were 84.87% and 84.59%, respectively, and the area under the curve was 0.905, which was higher than that of single detection, there are significant difference in those three groups(P< 0.05). Conclusion The combined detection of serum AFP, AFP-L3, GPC3 and MMP2 are the risk factors of HCC ppatients, which is helpful to the early diagnosis and treatment of cancer in high-risk patients with hepatocellular carcinoma, and improve survival time of patients and the survival rate.

Key words: Alpha fetoprotein, Alpha fetoprotein variants-L3, Glypican 3, Matrix metalloproteinase 2, Hepatocellular carcinoma

庞文箫, 李继科, 陈廷玉, 赵勇, 魏国. 甲胎蛋白及其异质体、磷脂酰肌醇蛋白聚糖3和基质金属蛋白酶2联合检测在肝细胞癌中的诊断价值[J]. 新发传染病电子杂志, 2022, 7(4): 33-36.

Pang Wenxiao, Li Jike, Chen Tingyu, Zhao Yong, Wei Guo. The value of AFP combined with AFP-L3, GPC3 and MMP2 detection in the diagnosis of hepatocellular carcinoma[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(4): 33-36.

参考文献

[1] WONG M CS, JIANG JY, GOGGINS WB, et al.International incidence and mortality trends of liver cancer: a global profile[J]. Sci Rep, 2017, 7(1):846-855.
[2] YARCHOAN M, AGARWAL P, VLLANUEVAL A, et al.Recent Developments and Therapeutic Strategies against Hepatocellular Carcinoma[J]. Cancer Res, 2019, 79(17):4326-4330.
[3] SCHEAU C, BADARAU IA, CARUNTU C, et al.Capsaicin: Effects on the Pathogenesis of Hepatocellular Carcinoma[J]. Molecules, 2019, 24(13):350-366.
[4] ZONG J, FAN Z, ZHANG Y.Serum Tumor Markers for Early Diagnosis of Primary Hepatocellular Carcinoma[J]. J Hepatocell Carcinoma, 2020, 7:413-422.
[5] 高娟, 李盼盼. AFP、AFP-L3%与GP73联合检测对原发性肝癌的诊断价值[J]. 数理医药学杂志, 2022, 35(1):112-114.
[6] LONGERICH T.Hepatocellular carcinoma[J]. Der Pathologe, 2020, 41(5):478-487.
[7] CHEN L, YI X, GUO P, et al.The role of bone marrow-derived cells in the origin of liver cancer revealed by single-cell sequencing[J]. Cancer Biol Med, 2020, 17(1):142-153.
[8] TANG W, CHEN Z, ZHANG W, et al.The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects[J]. Signal Transduct Target Ther, 2020, 5(1):87-102.
[9] HUANG A, YANG XR, CHUNG WY, et al.Targeted therapy for hepatocellular carcinoma[J]. Signal Transduct Target Ther, 2020, 5(1):146-159.
[10] MEJIA JC, PASKO J.Primary Liver Cancers[J]. Surg Clin North Am, 2020, 100(3):535-549.
[11] LIU W, ZHANG F, QUAN B, et al.The Prognostic Value of the Albumin to Gamma-Glutamyltransferase Ratio in Patients with Hepatocellular Carcinoma Undergoing Radiofrequency Ablation[J]. Dis Markers, 2021, 2021:1-10.
[12] ASSALINO M, TERRAZ S, GRAT M, et al.Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi‐center retrospective cohort study[J]. Trans Inter, 2020, 33(5):567-575.
[13] MAZZOTTA AD, PASCOLE A, CANO L, et al.Number of hepatocellular carcinoma nodules in patients listed for liver transplantation within alpha‐fetoprotein score: a new prognostic risk factor[J]. Trans Inter, 2021, 34(5):954-963.
[14] XU W, ZHANG Z, ZHANG Y, et al.alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma[J]. Onco Targets Ther, 2015, 9:123-129.
[15] ZHOU JM, WANG T, ZHANG KH.AFP-L3 for the diagnosis of early hepatocellular carcinoma[J]. Med, 2021, 100(43):e27673.
[16] CHEN S, LI J, TAN X, et al.Clinical role of combining alpha‐fetoprotein and lens culinaris agglutinin‐reactive fraction of alpha‐fetoprotein for hepatocellular carcinoma: Evidence from literature and an original study[J]. J Clin Lab Anal, 2020, 34(7):e23262.
[17] KAMIMURA K, MAEDA N.Glypicans and Heparan Sulfate in Synaptic Development, Neural Plasticity, and Neurological Disorders[J]. Front Neural Circuits 2021, 15(10):596-613.
[18] FILMUS J, CAPURRO M, RAST J.Glypicans[J]. Genome Biol, 2008, 9(5):224-230.
[19] NASHIDA T, KATAOKA H.Glypican 3-Targeted Therapy in Hepatocellular Carcinoma[J]. Cancers 2019, 11(9):13-39.
[20] TSUCHIYA N.Biomarkers for the early diagnosis of hepatocellular carcinoma[J]. World J Gastroenterol, 2015, 21(37):573-583.
[21] FU Y, URBAN DJ, NANI RR, et al.Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma[J]. Hepatology, 2019, 70(2):563-576.
[22] SUN L, GAO F, Gao Z, et al.Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma[J]. J Immunother Cancer, 2021, 9(4):e001875.
[23] ZHANG L, LIU H, SUN L, et al.Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: A tissue microarray-based study[J]. Acta Histochem, 2012, 114(6):547-552.
[24] CUI N, HU M, Khalil RA.Biochemical and Biological Attributes of Matrix Metalloproteinases[J]. Prog Mol Biol Transl Sci, 2017, 147:1-73.
[25] PASTUSHANKU I, MAURI F, SONG Y, et al.Fat1 deletion promotes hybrid EMT state, tumour stemness and metastasis[J]. Nature, 2020, 589(7842):448-455.
[26] WANG BIN, DING YM, Fan P, et al.Expression and significance of MMP2 and HIF-1α in hepatocellular carcinoma[J]. Onco Lett, 2014, 8(2):539-546.
[27] SCHOEDEL KE, TYNER VZ, KIM TH, et al.HGF, MET, and Matrix-Related Proteases in Hepatocellular Carcinoma, Fibrolamellar Variant, Cirrhotic and Normal Liver[J]. Mod Pathol, 2003, 16(1):14-21.

甲胎蛋白及其异质体、磷脂酰肌醇蛋白聚糖3和基质金属蛋白酶2联合检测在肝细胞癌中的诊断价值

The value of AFP combined with AFP-L3, GPC3 and MMP2 detection in the diagnosis of hepatocellular carcinoma

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 5

编辑推荐

Metrics

本文评价

[1]	陈圆圆, 程文兵, 陈川铁, 朱质斌, 黄德良, 陈燕平, 陈军. 异常凝血酶原和甲胎蛋白异质体比率联合检测在AFP阴性HBV相关HCC诊断中的作用[J]. 新发传染病电子杂志, 2022, 7(4): 25-28.
[2]	杜艳妮, 吕志彬, 邢玉雪, 关春爽, 张紫欣, 谢汝明, 陈步东. 乙型肝炎背景下肝细胞癌钆塞酸二钠增强MRI与组织学分化程度相关性分析[J]. 新发传染病电子杂志, 2022, 7(4): 47-52.
[3]	李晓月, 李述捷, 易永祥. 乙型肝炎病毒和丙型肝炎病毒相关性肝细胞癌的研究进展[J]. 新发传染病电子杂志, 2022, 7(1): 92-99.
[4]	马陈斌, 田芝奥. 肝宁片联合恩替卡韦治疗甲胎蛋白升高乙型肝炎疗效分析[J]. 新发传染病电子杂志, 2021, 6(4): 339-342.
[5]	乐晓华, 刘琢冰, 张香梅, 汪海燕, 曾丽娇, 郑娟, 姜楠, 刘威龙. 乙型肝炎患者肝细胞癌着丝粒蛋白K基因启动子区域甲基化水平的初步分析[J]. 新发传染病电子杂志, 2021, 6(2): 84-87.